Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 20, 2026
Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?
View original at finance.yahoo.comShould You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance? Johnson & Johnson JNJ announced robust second-quarter 2026 results on July 15, beating estimates for both earnings and sales…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Icotyde has the potential to revolutionize the treatment of plaque psoriasis with a once-a-day pill and has the potential to be J&J's largest product ever, with $10 billion in sales potential
60% confidenceJ&J expects continued above-market growth through the remainder of 2026
60% confidenceJ&J believes that nipocalimab (Imaavy) has pipeline-in-a-product potential
60% confidenceJ&J expects its Innovative Medicine segment to remain a key growth driver in the second half of 2026, with growth expected to be driven by key products and new launches offsetting the ongoing impact of Stelara biosimilar competition
60% confidence
Data points we hold from this source
| Johnson & Johnson Services, Inc. · earnings | 4.7 percent |